{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:43:46Z","timestamp":1760550226569},"reference-count":21,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p> CONTEXT Systemic mastocytosis is defined as a clonal disorder of mast cells and their precursor cells and is currently classified as a myeloproliferative neoplasm. Its clinical course has a wide spectrum, ranging from indolent disease, with normal life expectancy, to highly aggressive disease, associated with multisystemic involvement and poor overall survival. The aim of this study was to report a case of indolent systemic mastocytosis, focusing on the diagnostic challenges, with a review of the literature.   CASE REPORT A 79-year-old Caucasian woman with osteoporosis was evaluated at the Emergency Department because of complaints of low back pain. Before this, she had consulted an orthopedist and had undergone some imaging examinations, namely a bone scan that revealed a \u201csuperscan\u201d pattern. Due to her pain complaints and these test results, the patient was admitted to the Department of Internal Medicine. After undergoing several analytical tests and some additional imaging examinations to rule out some important differential diagnoses, she then underwent bone marrow biopsy, which made it possible to identify indolent systemic mastocytosis.   CONCLUSION Systemic mastocytosis is a rare entity that is difficult to diagnose. Its symptoms are often unspecific and frequently ignored. Skeletal changes may be the first and only manifestation of the disease and in some cases, like this one, the diagnosis is made only after histological examination. The key point for the diagnosis is to contemplate the possibility of systemic mastocytosis.<\/jats:p>","DOI":"10.1590\/1516-3180.2013.1313460","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T21:10:38Z","timestamp":1488921038000},"page":"198-204","source":"Crossref","is-referenced-by-count":8,"title":["Indolent systemic mastocytosis limited to the bone: a case report and review of the literature"],"prefix":"10.1590","volume":"131","author":[{"given":"Pedro","family":"Pinto-Lopes","sequence":"first","affiliation":[{"name":"Hospital Sao Joao,  Portugal"}]},{"given":"Francisco Adao","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Hospital Sao Joao,  Portugal"}]},{"given":"Roberto","family":"Silva","sequence":"additional","affiliation":[{"name":"Hospital Sao Joao,  Portugal"}]},{"given":"Pedro von","family":"Hafe","sequence":"additional","affiliation":[{"name":"Hospital Sao Joao,  Portugal"}]},{"given":"Elsa","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP),  Portugal"}]}],"member":"530","reference":[{"issue":"(5)","key":"ref1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman JW","year":"2009","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin C","year":"2004","journal-title":"Annu Rev Med"},{"issue":"(1)","key":"ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms","volume":"114","author":"Valent P","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"ref4","series-title":"(eds). Harrison's principles of internal medicine. 18<sup>th<\/sup> ed","first-page":"2707","author":"Long DL","year":"2011"},{"key":"ref5","article-title":"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic).","author":"Castelles MC","journal-title":"UpToDate"},{"key":"ref6","first-page":"126","article-title":"Mastocytosis presenting as a skeletal disorder","volume":"16","author":"Delsignore JL","year":"1996","journal-title":"Iowa Orthop J"},{"issue":"(12)","key":"ref7","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S1357-2725(03)00208-5","article-title":"Mast cells in allergy and beyond","volume":"35","author":"Puxeddu I","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"issue":"(7)","key":"ref8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero AC","year":"2006","journal-title":"Blood"},{"issue":"(6)","key":"ref9","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir N","year":"2008","journal-title":"Blood"},{"issue":"(2)","key":"ref10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz AS","year":"2002","journal-title":"Blood"},{"issue":"(24)","key":"ref11","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1002\/cncr.26256","article-title":"Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis","volume":"117","author":"Quint\u00e1s-Cardama A","year":"2011","journal-title":"Cancer"},{"key":"ref12","article-title":"Systemic mastocytosis. Medscape Reference.","author":"Krishnan K","journal-title":"Drugs, Diseades & Procedure"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s003300050554","article-title":"Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features","volume":"8","author":"Narv\u00e1ez JA","year":"1998","journal-title":"Eur Radiol"},{"issue":"(18)","key":"ref14","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani A","year":"2009","journal-title":"Blood"},{"key":"ref15","article-title":"Treatment and prognosis of systemic mastocytosis.","author":"Castelles MC","journal-title":"UpToDate"},{"issue":"(5)","key":"ref16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","article-title":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","volume":"108","author":"Bell MC","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"(6)","key":"ref17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings GJ","year":"2011","journal-title":"Intern Med"},{"issue":"(1)","key":"ref18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin C","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"(11)","key":"ref19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz A","year":"2009","journal-title":"Leuk Res"},{"issue":"(12)","key":"ref20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul C","year":"2010","journal-title":"Am J Hematol"},{"issue":"(11)","key":"ref21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger KJ","year":"2008","journal-title":"Eur J Clin Invest"}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v131n3\/1516-3180-spmj-131-03-198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T16:10:54Z","timestamp":1495901454000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802013000300198&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"alternative-id":["S1516-31802013000300198"],"URL":"https:\/\/doi.org\/10.1590\/1516-3180.2013.1313460","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}